DOC

Volume , Number

By Tina Matthews,2014-06-26 21:45
15 views 0
Volume , Number ...

    for health professionals who care for cancer patients November 2002 Volume 5, Number 11 Available on website www.bccancer.bc.ca

    ? Busulfan Injectable - changed to Class I for

     INSIDE THIS ISSUE pediatric patients who cannot swallow oral

    busulfan ? Benefit Drug List - busulfan injectable, ? Cabergoline - changed to Class I for second cabergoline, docetaxel, fludarabine oral tablet,

    gemcitabine, interferon, irinotecan, paclitaxel, line suppressive therapy for prolactinomas

    temozolomide, trastuzumab (CNCAB) ? Protocol Update BRAVCAD, BRAVDOC, ? Docetaxel - new class II indications for breast BRAVDOC7, BRAVEXE, BRAVTR, CNCAB, cancer (BRAVDOC7) and prostate cancer CNMODPCV, CNTEMOZ, GIIRINALT, (GUPDOC) GOOVCATR, GOOVGEM, GUBVAL, ? Fludarabine Oral Tablet - added to Class I GUPDOC, UGUTAXGEM, UHNRAMI, as an alternative to fludarabine injectable ULUCISDOC, LUDOC, LUPG, LYCHOP,

    (LYFLU) LYECV, LYFLU, LYGDP, LYICE, LYIT,

    LYPALL, SAAJA, SMAJIFN ? Gemcitabine - new Class II indications added ? Cancer Management Manual for gynecological cancers (GOOVGEM),

    ? Pre-Printed Order Update BRAJCEF, lymphoma (LYGDP, LYPALL) and

    BRAJCEF-G, BRAVNAV, BRAVTRNAV, mesothelioma (LUPG); new indication BRAVTRAP, BRINFCEF, BRINFCEF-G, (Undesignated Indication approval required for BRLACEF, BRLACEF-G, UGIFOLFOX, each patient) added for germ cell cancers using LYCHOP-R paclitaxel and gemcitabine (UGUTAXGEM) ? Patient Education Update amifostine, ? Interferon - Class II indication added for fludarabine oral, goserelin, leuprolide,

    melanoma (SMAJIFN) valrubicin

    ? Irinotecan - Class II indication revised for ? Drug Update amifostine

    colorectal cancer (GIIRINALT) ? Cancer Drug Manual

    ? Paclitaxel (Undesignated Indication approval ? Nursing Practice Update

    required for each patient) Palliative therapy for ? Focus On

    germ cell cancers using paclitaxel and ? Provincial Systemic Therapy Program Policies

     III-50 gemcitabine (UGUTAXGEM) ? Communities Oncology Network ? Temozolomide - Class II indications revised ? Library/Cancer Information Centre for brain tumours (CNTEMOZ)

    Unconventional Drug Therapies Manual ? Trastuzumab - Class II indication added as ? Continuing Education Presentation on single agent therapy for breast cancer Symptom Management, BC Cancer Agency (BRAVTR) Annual Cancer Conference If applicable, a Class II form or Undesignated FAX request form and IN TOUCH phone list are Indication application must be completed and provided if additional information is needed. submitted to the Provincial Systemic Therapy Program before the drug will be dispensed at a

    BENEFIT DRUG LIST regional cancer centre or reimbursed to a community

    The following changes have been made to the Benefit hospital. The current Benefit Drug List, Class II

    Drug List by the Provincial Systemic Therapy forms and Undesignated Indication application forms

    Program effective 1 November 2002: are available on the BC Cancer Agency website

     (www.bccancer.bc.ca) under Health Professionals Info,

    Chemotherapy Protocols, Frequently Used Forms.

    British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

     2 better than those treated with simple standard out-

    HIGHLIGHT OF PROTOCOL CHANGES patient chemotherapy.

     Third, oral fludarabine tablets are now available in Breast Two new protocols have been introduced.

    Canada and has been added as an alternative to the The first, one, BRAVDOC7, is a new weekly

    intravenous fludarabine in the LYFLU regimen. docetaxel regimen introduced as an additional option 2 Note that the dose of oral fludarabine is 40 mg/mfor patients with poor tolerance to BRAVDOC or

    and the need for dose reduction or avoidance of this high doses of dexamethasone used for the protocol. agent in the face of renal dysfunction stillapplies. Weekly docetaxel has been shown to be active and

     Fourth, gemcitabine is added as a palliative agent well tolerated by elderly and/or poor performance

    for the treatment of relapsed Hodgkin’s lymphoma status patients with advanced breast cancer. The

    and peripheral T-cell lymphoma (LYPALL). Phase second protocol, BRAVTR, is the use of the HER-2

    II studies have shown that gemcitabine is an active monoclonal antibody, trastuzumab, as a single agent

    drug for many different types of lymphomas. Based palliative therapy in patients with HER-2 positive

    on the literature and our own intra-provincial metastatic breast cancer.

    experience, the response rate to single agent

    gemcitabine for advanced relapsed Hodgkin’s Head and Neck UHNRAMI is a new treatment

    lymphoma, peripheral T-cell lymphoma and mycosis protocol that employs amifostine, a radioprotective

    fungoides is in the 50 percent or higher range. A agent, in the setting of radical/curative radiotherapy

    completed Class II form is required for the use of for head and neck cancers. Patients treated with

    gemcitabine for this indication. high dose radiation for head and neck cancers often

     Finally, the use of intrathecal chemoprophylaxis experience dose-limiting mucositis and xerostomia

    (LYIT) has been revised for patients with bone when substantial amount of salivary glands are

    marrow positive diffuse large cell lymphoma who included in the treatment fields. Xerostomia can

    have reached a complete remission. Based on recent result in substantial impact on patients’ quality of

    publications and our own internal BC data, life due to the associated difficulty with speaking and

    intrathecal therapy is no longer recommended for eating, increased risk for dental caries, loss of teeth,

    patients with bone marrow positive diffuse large cell oral bone loss and infections. See Drug Update

    lymphoma of B- or T-cell type, advanced stage for more details on amifostine.

    testicular diffuse large B-cell lymphoma and

    epidural diffuse large B-cell lymphoma. However, Lymphoma A number of changes in the treatment chemoprophylaxis should continue to be given to of lymphomas are introduced in this issue. First, the patients with paranasal sinus lymphoma. use of the LYICE (ifosfamide, carboplatin, etoposide) protocol for relapsed aggressive histology lymphoma Neuro-Oncology The indications of temozolomide is replaced by the LYGDP (gemcitabine, (CNTEMOZ) has been revised to include first line dexamethasone, cisplatin) regimen. Unlike the therapy for low grade oligodendrogliomas (12 LYICE protocol which requires a 3-4 day cycles), as well as a first line alternative to lomustine hospitalization and routine filgrastim, the LYGDP is (CNCCNU) and the PCV (procarbazine, lomustine, an entirely out-patient regimen and filgrastim is not vincristine) regimen (CNMODPCV) for recurrent usually needed. These two regimens appear to be malignant gliomas and anaplastic equally effective based on the available phase II data. oligodendrogliomas. A completed Class II form is required for the use of gemcitabine for this indication. Sarcoma The use of an adjuvant doxorubicin Second, the high-dose LYECV (etoposide, therapy regimen (SAAJA) is now recommended for cyclophosphamide, vincristine) regimen will no all healthy patients with high grade (Gr 2 or 3), large longer be recommended for patients with advanced (5 cm or greater) soft tissue sarcomas (STS) stage mantle cell lymphoma. The current involving the extremities. This recommendation is recommendation is to treat with 6 cycles of based on the findings of the Sarcoma Meta-Analysis LYCHOP protocol instead. This decision is based Collaboration (SMAC) of the Cochrane on the fact that there is now sufficient information to Collaborative. The SMAC report combined the show that these patients are not doing sufficiently

    British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

     3 results of 14 randomized trials that treated STS ? GIIRINALT revised (requirement for

    patients comparing doxorubicin-based regimens with undesignated indication approval removed): no treatment. There was significant benefit for all Second-line treatment for 5-FU refractory STS patients in terms of local relapse free rate, metastatic colorectal cancer using weekly distant recurrence free rate, relapse free survival rate scheduled irinotecan and a trend for improved overall survival, as well as ? GOOVCATR revised (dose modifications)

    a significant 7% improvement in overall survival for Second line treatment using paclitaxel and the subset of extremity STS patients. The carboplatin for epithelial ovarian cancer eligibility of adjuvant doxorubicin therapy would not relapsing after primary treatment be limited by age, though premorbid health status ? GOOVGEM new: Palliative chemotherapy for and perceived ability to tolerate full doses of this re-treatment of ovarian, tubal, and peritoneal treatment should be taken into account before cancer using gemcitabine making a definite recommendation. ? GUBVAL new: Palliative therapy for BCG-

     refractory bladder Tis in patients unfit for

    LIST OF NEW AND REVISED PROTOCOLS cystectomy using intravesical valrubicin

    ? GUPDOC new: Palliative therapy for INDEX to BC Cancer Agency Protocol

    metastatic hormone refractory prostate cancer Summaries revised monthly (includes tumour

    using docetaxel group, protocol code, indication, drugs, last revision

    ? UGUTAXGEM new (Undesignated Indication date and version). Protocol codes for treatments

    approval required for each patient): Palliative requiring “Undesignated Indication” approval prior

    therapy for germ cell cancers using paclitaxel to use are prefixed with the letter U.

    and gemcitabine ? BRAVCAD revised (docetaxel dilution volume

    ? UHNRAMI new: Radioprotection in head and and infusion rate): Palliative therapy for

    neck radiation using amifostine metastatic breast cancer using docetaxel and

    ? ULUCISDOC revised (docetaxel dilution capecitabine

    volume and infusion rate): First-line treatment ? BRAVDOC revised (docetaxel dilution volume

    for advanced non-small cell lung cancer with and infusion rate): Palliative therapy for

    docetaxel (Taxotere?) and cisplatin metastatic breast cancer using Docetaxel ?? LUDOC revised (docetaxel dilution volume and (Taxotere)

    infusion rate): Second-line treatment for ? BRAVDOC7 new: Palliative therapy for

    advanced non-small cell lung cancer (NSCLC) metastatic breast cancer using weekly docetaxel

    with docetaxel (Taxotere?) (Taxotere?)

    ? LUPG revised (requirement for undesignated ? BRAVEXE revised (eligibility): Palliative

    indication approval removed): Treatment of Therapy for advanced breast cancer using

    malignant mesothelioma with cisplatin and exemestane (Aromasin?) gemcitabine ? BRAVTR revised (requirement for undesignated ? LYCHOP revised (eligibility for intrathecal indication approval removed): Palliative therapy chemotherapy): Treatment of lymphoma with for metastatic breast cancer using trastuzumab doxorubicin, cyclophosphamide, vincristine and (Herceptin?) prednisone ? CNCAB revised (class form requirement ? LYECV revised (indication for Mantle cell removed): Second line suppressive therapy for lymphoma deleted): Consolidation for lymphoma prolactinomas using cabergoline using etoposide and cyclophosphamide and ? CNMODPCV revised (number of treatment vincristine cycles, maximum vincristine dose, vincristine ? LYFLU revised (oral fludarabine added): dilution): Modified PCV chemotherapy of brain Treatment of low grade lymphoma or chronic tumours using procarbazine, lomustine (CCNU) lymphocytic leukemia with fludarabine and vincristine ? LYGDP new (replacing LYICE): Treatment of ? CNTEMOZ revised (title, eligibility, antiemetics lymphoma with gemcitabine, dexamethasone and and treatment cycles): First line therapy for cisplatin malignant brain tumours using temozolomide

    British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

     4 ? LYICE deleted (replaced by LYGDP): for recurrent breast cancer refractory to Treatment of lymphoma with ifosfamide, anthracycline adjuvant chemotherapy carboplatin and etoposide ? BRINFCEF revised (reformatted): Therapy for

    ? LYIT revised (eligibility, tests, treatment): inflammatory breast cancer using Treatment of lymphoma using intrathecal cyclophosphamide, epirubicin and fluorouracil methotrexate and cytarabine ? BRINFCEF-G new: Therapy for inflammatory

    ? LYPALL revised (gemcitabine added): breast cancer using cyclophosphamide, Lymphoma palliative chemotherapy epirubicin, fluorouracil and filgrastim (G-CSF)

    ? SAAJA new: Doxorubicin for adjuvant use for ? BRLACEF revised (reformatted): Therapy for patients with non-metastatic operable large high locally advanced breast cancer using grade soft tissue sarcoma cyclophosphamide, epirubicin and fluorouracil.

    ? SMAJIFN revised (requirement for ? BRLACEF-G new: Therapy for locally undesignated indication approval removed): advanced breast cancer using cyclophosphamide, Adjuvant therapy of high risk malignant epirubicin, fluorouracil and filgrastim (G-CSF)

    ? UGIFOLFOX new: Palliative combination melanoma with high dose interferon (HDIFN) ?-

    chemotherapy for metastatic colorectal cancer 2b

    using oxaliplatin, 5-fluorouracil and folinic acid Protocols are available on the BC Cancer Agency

    (leucovorin)website (www.bccancer.bc.ca) under Health

    Professionals Info, Chemotherapy Protocols. ? LYCHOP-R revised (booking time): Treatment

     of lymphoma with doxorubicin,

    cyclophosphamide, vincristine, prednisone and CANCER MANAGEMENT MANUAL

    rituximab The Cancer Management Manual is available are

     available on the BC Cancer Agency website

    PATIENT EDUCATION UPDATE (www.bccancer.bc.ca) under Health Professionals

    Amifostine Patient Information Handout is Info, Cancer Management Guidelines.

    now available. Amifostine is used as radioprotective

    agent for patients receiving high dose radiation. See PRE-PRINTED ORDER UPDATE

    Drug Update for more information. Pre-printed orders should always be checked with

     the most current BC Cancer Agency protocol

    Fludarabine (Oral) Patient Information summaries. The BC Cancer Agency Vancouver

    Handout is now available. Centre has prepared chemotherapy pre-printed

     orders, which can be used as a guide for reference.

    Goserelin and Leuprolide Patient An index to the orders can be obtained by Fax-back.

    Information Handouts have been corrected for ? BRAJCEF revised (reformatted): Adjuvant

    typographical error. therapy for breast cancer using

     cyclophosphamide, epirubicin and fluorouracil

    Valrubicin Patient Information Handout is ? BRAJCEF-G new: Adjuvant therapy for breast

    now available. cancer using cyclophosphamide, epirubicin, fluorouracil and filgrastim (G-CSF) Patient information handouts for cancer drugs are ? BRAVNAV revised (tests, premedications, available on the BC Cancer Agency website precautions): Palliative therapy for metastatic (www.bccancer.bc.ca) under Health Professionals breast cancer using vinorelbine (Navelbine?) Info, Drug Database. ? BRAVTRNAV revised (bookings for 3-weekly doctor's appointments): Palliative therapy for DRUG UPDATE metastatic breast cancer using trastuzumab

    Amifostine is a sulfhydryl prodrug used as a (Herceptin?) and vinorelbine

    radioprotective and cytoprotective agent. Its active ? BRAVTRAP revised (eligibility to be consistent

    metabolite is readily taken up by cells where it acts with protocol): Palliative therapy for metastatic

    by scavenging the free radicals generated in tissues breast cancer using trastuzumab (Herceptin?)

    exposed to radiation and chemotherapy, as well as and paclitaxel (Taxol?) as first-line treatment

    British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

     5 reactive metabolites of cisplatin and alkylating used (and requested) nursing references include agents. Healthy cells are protected preferentially due current procedures for Central venous catheter care, to increased uptake of amifostine and more rapid including PICC, IVAD and Hickman lines care. metabolism to the active sulfhydryl metabolite We are committed to making current references and because of greater phosphatase activity and higher resources readily available to all BCCA nurses. In pH, as compared to tumour cells. Amifostine and the next few months you will note a progressive metabolites have been shown to be present in 100 move to include more nursing information on the times the concentration in healthy cells compared to BCCA website. Stand by for updates on this area!

     tumour cells.

    Submitted by

    Judy Oliver Changes in Special Access Programme

    Education Resource Nurse Health Canada has recently changed its requirements

     for accepting requests for Special Access

    Survey Results for Pharmacy Professional Programme (SAP) medications such as amifostine,

    Development In July 2002, the Pharmacy CON bexarotene, oxaliplatin and thalidomide. The major

    Educators distributed a professional development change is to require the use of the Health Canada

    needs assessment survey to 80 CON pharmacists form when requesting a SAP medication and to

    throughout British Columbia. The survey is now require the physician's consent to the following

    complete and the results have been processed. statements:

    Thank you to all of you who contributed to the ? I am aware that by accessing this drug through

    survey and resubmitted the information a second the SAP, the sale of the drug is exempt from all

    time when a technical error erased the original data. aspects of the Food and Drugs Regulations

    Eighty surveys were distributed and fifty-one including those respecting the safety, efficacy

    responses were received. This represented a return and quality.

    rate of 64%. ? I agree to provide a report on the results of the

     The purpose of Section One was to develop a use of the drug including information on Adverse

    profile of the CON pharmacist. We learned that the Drug Reactions in accordance with the current

    majority of the respondents were involved in some regulations and, on request, to account for

    aspect of their hospital’s oncology practice: quantities of the drug received.

    preparation of cytotoxics, training of staff,

    dispensing, clinical, counselling patients and billings. The link to the Health Canada SAP form can be

    For 51% of the respondents, oncology-related found on the BC Cancer Agency website

    activities represented less than 25% of their hospital (www.bccancer.bc.ca) under Health Professionals

    practice. Eighty percent said that oncology Info, Chemotherapy Protocols, Frequently Used

    represented less that 50% of their hospital practice. Forms, or directly from Health Canada website.

     This section also identified that technicians play an

     integral part of CON practice. Eighty-six percent of

    CANCER DRUG MANUAL the respondents stated that technicians are involved

    in the preparation of parenteral cytotoxic drugs at The Cancer Drug Manual is available on the BC

    their hospital. Sixty-four percent of the technicians Cancer Agency website www.bccancer.bc.ca/cdm/.

     were trained by other technicians rather than by

    COMMUNITIES ONCOLOGY NETWORK pharmacists.

     In Section Two, the CON pharmacists were asked Increasing Access to BCCA Nursing

    where their priorities lie with respect to their Resources A common request from nurses

    pharmacy oncology practice. The top four priorities around the province is for greater access to

    in this area were identified to be: information about BCCA nursing procedures. while

    ? Interpretation and Clinical application of the agency policies related to safe administration and

    protocols handling of chemotherapy drugs are already included

    ? Guidelines for safe handling of cytotoxic in the website, other frequently-used documents are

    medications not yet available. Examples of other, frequently

    British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

     6 ? General management of chemotherapy side Changes in Contact Phone Number Please

    effects note that the following extensions have been changed:

    ? General concepts in oncology 1. CON billings: 6277 (previously 2515)

     We also identified key issues confronting the CON 2. Undesignated Indication Approval: 6277 pharmacists: staffing shortages, training needs and (previously 2515)

    budget constraints. These extensions can be reached through (604) 877-

     Section Three of the survey dealt with how best to 6098 or toll free 1-800-663-3333.

    deliver an oncology education program. The top

    four methods were: PROVINCIAL SYSTEMIC THERAPY ? Regional sessions at the nearest BCCA Centre PROGRAM POLICIES ? Practicums at Cancer Centres Policy on Administration of Intrathecal ? Web-based Chemotherapy The Policy on the Administration ? Text-based of Cytotoxic Drugs by the Intrathecal Route via Approximately 50% of the respondents have Lumbar Puncture or Ommaya Reservoir (Policy III-attended a BCCA Annual Cancer Conference in 50) has been revised to delete the cross-reference to November. Those that have not attended cited the vinca alkaloids labelling policy. reasons such as staffing, budget, travel or the fact that oncology was not a high priority in their hospital BC Cancer Agency Systemic Therapy Policies are practice. available on the BC Cancer Agency website The challenge now facing the CON Educators is to (www.bccancer.bc.ca) under Health Professionals design an oncology education program that will fit Info, Chemotherapy Protocols, Policies and the needs of as many of our CON partners as Procedures. possible. Our first step is to create an initially text- based educational module on “Interpretation and

    LIBRARY/CANCER INFORMATION CENTRE Clinical Application of Protocols.” A text-based

    Unconventional Cancer Therapies Manual is program is chosen because it is the most practical

    available on the BC Cancer Agency website and far-reaching, although it was not the first choice

    www.bccancer.bc.ca under Patient/Public Info, overall. Our plan is to pilot the first module early

    Unconventional Therapies. The manual consists of next year. Conversion to a web-based program,

    46 short monographs on the more commonly used practicums and regional sessions will be developed

    unconventional cancer therapies (e.g., Essiac, at a future date.

    vitamins, teas, shark cartilage) and includes tips for Our thanks to those who helped us achieve this

    the patient and family on how unconventional goal. As a show of our appreciation, we held a

    therapies can be evaluated. For each therapy the random draw from those who submitted their name

    manual provides proponent/advocate claims, as well after completion of the survey. The winners of a

    as evidence-based evaluation/critique quotations $75.00 book prize gift certificate were:

    from the literature. ? Karen Dusangh (Richmond General Hospital)

     ? Karen George (West Coast General Hospital)

    CONTINUING EDUCATION ? Terry Malo (Penticton Regional hospital)

    Presentation on Symptom Management ? Ian Petterson (Shuswap Lake Hospital)

    Karima Velji, an advanced practice nurse with an

    extensive background in cancer nursing practice, For more information on the development of the

    education, and research, will present "Implementing provincial pharmacy oncology-education program,

    please contact your regional Pharmacy CON Research in Practice: Symptom Management" on Educator. Wednesday evening, 27 November, 2002. Please

     join us at one of the four regional cancer centres for

    Submitted by a light dinner at 6 pm, followed by the video-linked

    Dawn Annable presentation at 7 pm.

    Pharmacy CON Educator-Fraser Valley

    British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

     7 For more details, please call: Vancouver Island

    Centre - Jodi Graham (250) 519-5573; Centre for

    the Southern Interior - Dixie Rosher (250) 712-3975; Editorial Review Board

    Vancouver and Fraser Valley Centres - Isabel Mário de Lemos, PharmD (Editor) Lundie (604) 877-6098, local 2623. Cicely Bryce, MD BCCA Annual Cancer Conference The BC Sandra Broughton, BA (Econ), MSc Cancer Agency will hold its Annual Cancer Karen Janes, MSN Conference 2002 at the Renaissance Harbourside Beth Morrison, MLS Hotel in Vancouver. Jaya Venkatesh, MHA Susan Walisser, BSc (Pharm) The 3-day agenda includes the Canadian Strategy for Cancer Control, Medical Scientific Conference and Gigi Concon (Secretary) Provincial Oncology Professionals meeting. The Partners in Care Conference on Thursday, November 28th will be devoted to Implementing the

    Canadian Strategy for Cancer Control in BC and

     Yukon, a workshop presented by the BC Cancer

     Agency (BCCA), Canadian Cancer Society (CCS)

     and Canadian Cancer Advocacy Network (CCAN). This workshop is by invitation only. The Medical/Scientific Conference on Friday November 29 all day and Saturday November 30 until noon is devoted to Immune System and

    Cancer.

     The Provincial Oncology Professionals will hold

     their discipline-specific education and business

     meetings on either Friday November 29 or Saturday November 30. For more details, please call (604) 877-6098 local 2744. Please don't forget to check out our website for further details! (www.bccancer.bc.ca/HPI/AnnualCancerConf/defau

    lt.htm)

    www.bccancer.bc.ca bulletin@bccancer.bc.ca IN TOUCH

    BC Cancer Agency (604)-877-6000 Toll-Free 1-(800)-663-3333 Communities Oncology Network Ext 2744 jvenkate@bccancer.bc.ca Education Resource Nurse Ext 2638 nursinged@bccancer.bc.ca Nursing Professional Practice Ext 2623 ilundie@bccancer.bc.ca Pharmacy Professional Practice Ext 2247 gconcon@bccancer.bc.ca Provincial Systemic Therapy Program Ext 2247 gconcon@bccancer.bc.ca Communities Oncology Network Pharmacist Ext 6277 francish@bccancer.bc.ca Drug Information Ext 6275 dcole@bccancer.bc.ca

    robrien@bccancer.bc.ca Library / Cancer Information Ext 2690 bethm@bccancer.bc.ca Update Editor Ext 2288 mdelemos@bccancer.bc.ca British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

     8 (250) 712-3900 Toll-Free 1-(888)-563-7773 Centre for the Southern Interior (CCSI)Fraser Valley Centre (FVCC) (604)-930-2098 Toll-Free 1-(800)-523-2885 Vancouver Centre (VCC) (604)-877-6000 Toll-Free 1-(800)-663-3333 Vancouver Island Centre (VICC) (250) 519-5500 Toll-Free 1-(800)-670-3322

    British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

     9

    REGIONAL CANCER CENTRE ACCESS

BULLETIN UPDATES LOCATION

    Cancer Drug Manual H:\everyone\systemic\chemo\cancer drug manual monographs Pre-Printed Orders H:\everyone\systemic\chemo\Orders\VCC

     Index of Pre-Printed Orders Index.doc

    BRAJCEF BRAVNAV BRAVTRAP BRINFCEF-G BRLACEF-G LYCHOP-R

    BRAJCEF-G BRAVTRNAV BRINFCEF BRLACEF UGIFOLFOX Protocol Summaries H:\everyone\systemic\chemo\Protocol\”tumour site”

     Index of Protocol Summaries Index_NT or Index_W6

    BRAVCAD CNCAB GOOVGEM ULUCISDOC LYFLU SAAJA

    BRAVDOC CNMODPCV GUBVAL LUDOC LYGDP SMJIFN

    BRAVDOC7 CNTEMOZ GUPDOC LUPG LYICE

    BRAVEXE GIIRINALT UGUTAXGELYCHOP LYIT

    M

    BRAVTR GOOVCATR UHNRAMI LYECV LYPALL Patient Education Handout H:\everyone\systemic\chemo\Pt Education

    Amifostine Fludarabine oral Goserelin Leuprolide Valrubicin Provincial Systemic Therapy Policies H:\everyone\systemic\chemo\policies

    III 50 - Administration of Cytotoxic Drugs by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir Reimbursement H:\everyone\systemic\chemo\Reimburs

     Benefit Drug List (1 Nov 2002) BenefitList.doc

     Class 2 Form (1 Nov 2002) Class2.doc

     Filgrastim Usage Form (Oct 2002) GCSF_form.doc

     Undesignated Indication Form (Nov Undesig.doc

    2002)

For easy access, double-click your systemic chemo icon.

    We appreciate your comments. Write us at bulletin@bccancer.bc.ca

    British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

     10

BC CANCER AGENCY SYSTEMIC THERAPY UPDATE FAX REQUEST FORM

    FAX (604) 877-0585

    bulletin@bccancer.bc.ca

    TO SUBSCRIBE: FAX OR EMAIL YOUR REQUEST OR CALL @ 877-6098 LOCAL 2247

    FOR URGENT REQUESTS PLEASE CALL (604) 877-6098 LOCAL 2247

    OR TOLL-FREE IN BC 1-800-663-3333 LOCAL 2247

    PLEASE FEEL FREE TO MAKE COPIES FOR YOUR COLLEAGUES I WOULD PREFER TO RECEIVE THIS INFORMATION VIA:

     E-mail (Word 6.0) @

     Fax ( ) Attn:

    UPDATES Please Fax-Back information below:

     All items

    Cancer Drug Manual Monographs (also available on our website www.bccancer.bc.ca)

    Patient Education Handout (also available on our website www.bccancer.bc.ca)

    Amifostine Fludarabine oral Goserelin Leuprolide Valrubicin Pre-printed Orders:

    BRAJCEF BRAVNAV BRAVTRAP BRINFCEF-G BRLACEF-G LYCHOP-R

    BRAJCEF-G BRAVTRNAV BRINFCEF BRLACEF UGIFOLFOX Protocol Summaries: (also available on our website www.bccancer.bc.ca)

    BRAVCAD CNCAB GOOVGEM ULUCISDOC LYFLU SAAJA

    BRAVDOC CNMODPCV GUBVAL LUDOC LYGDP SMJIFN

    BRAVDOC7 CNTEMOZ GUPDOC LUPG LYICE

    BRAVEXE GIIRINALT UGUTAXGELYCHOP LYIT

    M

    BRAVTR GOOVCATR UHNRAMI LYECV LYPALL

     Index: Protocol Summaries (current month)

    Provincial Systemic Therapy Program Policies

     III-50 Administration of Cytotoxic Drugs by the Intrathecal Route via Lumbar Puncture or Ommaya

    Reservoir

    Reimbursement (also available on our website www.bccancer.bc.ca)

     Benefit Drug List (01 Nov 2002)

     Class 2 Form (01 Nov 2002)

     Filgrastim Usage Form (October 2002)

     Undesignated Indication Form (Nov 2002)

    Systemic Therapy Update Index (also available on our website www.bccancer.bc.ca)

     Jan-Dec 2000

     Jan-Dec 2001

     Jan-Jun 2002

    British Columbia Cancer Agency ? Provincial Systemic Therapy Program Update ? Vol. 5 No. 11 2002

Report this document

For any questions or suggestions please email
cust-service@docsford.com